Chonluten vs Dermorphin
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
ChonlutenRecovery & Repair
Dermorphin- Summary
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Half-Life
- Short (minutes for the peptide); sustained gene-regulatory effects
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Admin Route
- SubQ, Oral
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- Research
- —
- —
- Typical Dose
- 10 mg per day
- Not established for human use; research doses vary widely
- Frequency
- Daily for 10–30 days
- Not established
- Key Benefits
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Side Effects
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Stacks With
- —
- —